ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3117

Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study

Lihi Eder1, Vinod Chandran1, Cheryl Rosen2, Jan Dutz3, James T. Elder4, Proton Rahman5, Christopher T. Ritchlin6, Francisco A. Tausk7, Sherry Rohekar8, Richard Hayday9, Snezana Barac10, Devy Zisman11, Joy Feld12 and Dafna D. Gladman1, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4University of Michigan Medical School, Ann Arbor, MI, 5Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, 6Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, 7University of Rochester Medical Center, Rochester, NY, 8Western University, London, ON, Canada, 9University of Manitoba, Winnipeg, MB, Canada, 10Winnipeg Clinic, Winnipeg, MB, Canada, 11Rheumatology Unit, Carmel Medical Center, Haifa, Israel, 12Carmel Medical Center, Haifa, Israel

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, Psoriatic arthritis, risk and treatment guidlelines

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis - CoMorbidities

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Cardiovascular risk in patients with psoriatic disease is partly attributed to the high prevalence of traditional cardiovascular risk factors in these patients. This study aimed to estimate the proportion of under-treatment of cardiovascular risk factors in an international multicentre cohort of patients with psoriasis and psoriatic arthritis (PsA).

Methods: A cross-sectional analysis of patients with psoriatic disease from the International Psoriasis and Arthritis Research Team (IPART) cohort was conducted. The presence of traditional modifiable cardiovascular risk factors (diabetes, hypertension, dyslipidemia, smoking and central obesity) and the use of appropriate therapies were determined based on patients’ report, physical examination and laboratory tests. The 10-year cardiovascular risk was calculated according to the Framingham Risk Score (FRS). Adherence with guidelines for the treatment of dyslipidemia (Stone et al. Circulation 2014;129:S1-45) and hypertension (James et al. JAMA 2014;311:507-20) was assessed. Chi-square and Cochran-Armitage trend test were used to compare categorical variables across groups.

Results: A total of 2254 patients (58.9% PsA, 41.1% psoriasis alone) from 8 centres in Canada, US and Israel were included. Their mean age was 52±13.8 years and 53% were males. 83.2% of the patients had at least one modifiable cardiovascular risk factor. Based on the FRS classification 30% of patients were in a high risk and 18% were in a moderate risk category. 6.1% of the patients had ischemic heart disease, 45.1% hypertension, 71.1% dyslipidemia, 12.6% diabetes, 54.3% central obesity and 17.3% were current smokers. A significant proportion of under-treatment of hypertension and dyslipidemia was found. 455 (20.4%) patients had uncontrolled blood pressure (43% of them were not on antihypertensive medications). Uncontrolled hypertension was associated with low level of education (p<0.001) and severe psoriasis (PASI≥10, p<0.001). 850 (37.9%) patients had an indication for statin therapy but were not using these medications. Under-treatment of dyslipidemia was more frequent in patients with PsA (p=0.005), those with low-level of education (p<0.001) and patients with severe psoriasis (p=0.03).

Conclusion: In a real-world setting, a large proportion of patients with psoriasis and PsA were undertreated for hypertension and hyperlipidaemia.


Disclosure: L. Eder, None; V. Chandran, None; C. Rosen, None; J. Dutz, None; J. T. Elder, None; P. Rahman, None; C. T. Ritchlin, None; F. A. Tausk, None; S. Rohekar, None; R. Hayday, None; S. Barac, None; D. Zisman, None; J. Feld, None; D. D. Gladman, None.

To cite this abstract in AMA style:

Eder L, Chandran V, Rosen C, Dutz J, Elder JT, Rahman P, Ritchlin CT, Tausk FA, Rohekar S, Hayday R, Barac S, Zisman D, Feld J, Gladman DD. Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/under-treatment-of-cardiovascular-risk-factors-in-patients-with-psoriatic-disease-an-international-multicentre-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/under-treatment-of-cardiovascular-risk-factors-in-patients-with-psoriatic-disease-an-international-multicentre-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology